Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years


STOCKHOLM, April 27, 2022 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational anti-am… Read full article


Leave a Reply

Your email address will not be published.